Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Oncology
Chondrosarcoma Treatment in Turkey
Chondrosarcoma is a rare type of bone cancer that originates in cartilage cells, most frequently in the pelvis, femur, or shoulder. It primarily affects middle-aged and older adults. Sufferers often seek medical evaluation for a persistent, dull ache, local swelling, or a palpable mass that gradually enlarges. Feasible treatment options depend on a meticulous specialist assessment. Compare hospitals in Turkey that treat Chondrosarcoma and get a free review of your medical records.
- Price from
- Price on request
- Clinics
- 2
- Treated with
- 1
Verified surgeons for Chondrosarcoma
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
About Chondrosarcoma
Chondrosarcoma is a rare type of bone cancer that originates in cartilage cells, most frequently in the pelvis, femur, or shoulder. It primarily affects middle-aged and older adults. Sufferers often seek medical evaluation for a persistent, dull ache, local swelling, or a palpable mass that gradually enlarges. Feasible treatment options depend on a meticulous specialist assessment.
Specialty: Oncology
Treatment options
Depending on the stage and your medical history, doctors may recommend:
Best Clinics for Chondrosarcoma Treatment in Turkey
Frequently asked questions
The cost of treating Chondrosarcoma depends on the diagnosis and the treatment chosen. Doctors first review your medical records — free of charge — and you then receive an itemised quote.
Options may include Complex Diagnostics of Chondrosarcoma. Your doctor chooses the approach after reviewing your tests and scans.
Chondrosarcoma is treated by Oncology specialists. 2 clinics in Turkey on our platform offer this treatment.
What Is Chondrosarcoma and Typical Symptoms
Chondrosarcoma is a rare primary bone cancer that originates in cartilage cells. Unlike osteosarcoma, which produces bone, chondrosarcoma forms cartilaginous matrix. It predominantly affects adults between 30 and 70 years old. The disease most frequently arises in the pelvis, femur, shoulder girdle, and ribs, though spinal and skull base occurrences also happen.
Most cases are conventional chondrosarcomas, graded from 1 (low grade, slow growing) to 3 (high grade, aggressive). Rare variants include clear-cell, mesenchymal, and dedifferentiated tumours. Symptoms usually develop gradually over months and include:
- Persistent bone pain: A deep, dull ache that worsens at night or during rest and does not ease with basic analgesics.
- Localised swelling or mass: A firm, slowly enlarging lump over the affected bone.
- Joint stiffness: Reduced range of movement when the tumour develops near a joint.
- Nerve compression: Tingling, numbness, or weakness when pelvic or spinal tumours press against regional nerves.
- Pathological fracture: Bone breakage under routine stress due to structural weakening by the tumour.
How Chondrosarcoma Is Diagnosed in Turkey
Accurate diagnosis requires multidisciplinary evaluation combining imaging, pathology, and specialist surgical review through dedicated oncology and orthopedics departments.
Diagnostic evaluations in Turkey typically involve:
- Magnetic Resonance Imaging (MRI): Assesses soft-tissue involvement, marrow infiltration, and relation to critical nerves and vessels.
- Computed Tomography (CT): Highlights cortical erosion and matrix calcifications, showing classic rings and arcs.
- Staging scans: Coordinated via check-ups-diagnostics, including chest CT, to assess potential lung spread.
- Core-needle biopsy: Planned precisely along the future surgical incision tract to avoid tumour cell seeding.
Patients travelling from abroad should bring:
- Original imaging discs (DICOM files) for all previous X-rays, CT scans, and MRIs.
- Histology slides and paraffin blocks from prior biopsies for second-opinion review.
- Previous surgical and pathology reports.
- Medical records covering current medications and cardiovascular health.
Treatment Options for Chondrosarcoma
Conventional chondrosarcoma is typically resistant to conventional chemotherapy and standard radiotherapy due to poor vascularity and slow cellular turnover. Surgical resection with clear margins remains the primary definitive treatment.
| Option | Typically used when | Things to know |
|---|---|---|
| Wide surgical resection | Intermediate- and high-grade conventional tumours, or pelvic lesions. | The tumour is removed with a healthy tissue margin; reconstruction with modular endoprostheses may follow. |
| Intralesional curettage | Selected low-grade central tumours in the limbs. | The lesion is scooped out and treated with local chemical or thermal adjuvants, followed by grafting. |
| Limb-sparing surgery | Extremity tumours where major nerves and blood vessels are spared. | Reconstruction restores skeletal integrity while avoiding amputation whenever technically feasible. |
| Particle or proton radiotherapy | Unresectable tumours, positive margins, or skull base and spine locations. | Coordinated with neurosurgery to deliver high-dose radiation while protecting the nervous system. |
| Systemic chemotherapy | Aggressive variants such as mesenchymal or dedifferentiated chondrosarcomas. | Used in select high-grade subtypes, though conventional tumours show limited sensitivity. |
Planning Chondrosarcoma Treatment in Turkey
Organising care in Turkey begins with a remote assessment. International patients submit imaging files and biopsy records for evaluation by a sarcoma board to verify treatment feasibility before travelling.
Stay duration depends on surgical complexity. Patients having intralesional curettage usually stay 10 to 14 days. Complex pelvic resections or extensive endoprosthetic limb reconstructions require 3 to 5 weeks for surgical recovery, wound monitoring, and early physical therapy guided by dedicated rehabilitation teams.
Before departure, specialists provide detailed English discharge documents, operative notes, and implant details. Long-term surveillance is arranged with your local physicians, requiring regular MRI and chest scans every 3 to 6 months initially.
When Travel Is Not Advisable and Urgent Warning Signs
Patients should not travel abroad if facing acute medical crises. Seek immediate local emergency care for:
- Sudden neurological deficits: Progressive leg weakness, numbness in the groin, or loss of bowel and bladder control, indicating spinal cord or nerve root compression.
- Acute severe pain and inability to walk: Suggesting a sudden pathological bone fracture.
- Sudden breathing difficulty: Acute shortness of breath or chest pain requiring prompt cardiopulmonary assessment.
- Signs of infection: Fever, chills, or spreading redness around previous biopsy or operative sites.
- Severe medical instability: Uncontrolled cardiovascular disease or deep vein thrombosis that makes flying dangerous.
Final decisions on treatment methods and travel readiness rest with the treating physician after thorough in-person clinical and diagnostic assessment.
Frequently asked questions
Conventional chondrosarcoma cells produce an abundant cartilaginous extracellular matrix with limited blood vessels, which impedes the delivery of cytotoxic drugs. Additionally, these tumour cells typically divide at a slow rate and express multidrug-resistance transport proteins that neutralise standard chemotherapy agents. As a result, systemic chemotherapy is generally reserved for rare, fast-dividing subtypes such as mesenchymal or dedifferentiated chondrosarcomas, under the specific direction of an oncologist.
En bloc resection removes the tumour in one continuous piece surrounded by a margin of healthy tissue, reducing local recurrence risk for aggressive or high-grade lesions. Intralesional curettage scrapes out the tumour from inside the bone cavity, preserving skeletal structure. Curettage is strictly restricted to selected low-grade central tumours and is accompanied by local chemical or thermal adjuvants. Your surgical team determines the appropriate procedure based on histology, location, and imaging.
In the vast majority of cases, modern surgical techniques allow for limb-sparing surgery. Amputation is considered only when the tumour extensively encases major blood vessels and primary nerves, or when complete surgical removal would leave a non-functional limb. Surgeons use customised prosthetic replacements, modular endoprostheses, or bone allografts to rebuild the affected joint or bone. Your surgical team reviews detailed MRI scans to evaluate whether clear margins can be achieved while preserving the limb.
Chondrosarcoma cells can seed along the path created by a biopsy needle or incision during initial diagnostic tissue sampling. If the biopsy tract is left behind during definitive surgery, displaced malignant cells may trigger a local recurrence in the soft tissue. Therefore, surgical oncologists carefully plan the biopsy trajectory so that the entire tract, skin entry site, and adjacent tissue can be excised in continuity with the primary tumour specimen.
Because chondrosarcomas can recur locally or metastasise to the lungs years after initial treatment, regular long-term surveillance is vital. Patients typically undergo local site MRI examinations and chest CT imaging every three to six months for the first three years, transitioning to six-monthly and then annual checks up to ten years. These scans monitor surgical reconstruction integrity and detect any recurrence early. Your treating hospital provides written surveillance schedules for your local doctors.